-
Bempedoic acid: a non-statin option for LDL-C lowering
차정준 고려의대 순환기내과 08:30~08:48 -
The evolving landscape of PCSK9 inhibitors: siRNA, oral agents, and mAbs
안준호 전남의대 순환기내과 08:48~09:06 -
Lp(a)-lowering therapies: olpasiran and other emerging agents
최성훈 한림의대 순환기내과 09:06~09:24 -
CETP inhibitors: revisiting an old target with new molecules
홍준화 을지의대 내분비내과 09:24~09:42 - Panel Discussion 09:42~10:00
-
Updated risk stratification and treatment pathways in the 2026 Korean guidelines
정재훈 동국의대 심장내과 13:10~13:28 -
Optimizing pharmacologic therapy in the 2026 Korean guidelines
오진경 충남의대 심장내과 13:28~13:46 -
Lifestyle interventions in dyslipidemia care: evidence updates and practical recommendations for Korea
조가람 고려대 보건과학대학 13:46~14:04 -
Managing dyslipidemia in special population in the 2026 Korean guidelines
장영우 가천의대 심장내과 14:04~14:22 - Panel Discussion 14:22~14:40
-
From basic discovery to clinical translation: macrophage-targeted imaging and therapy for high-risk plaque
김진원 고려의대 순환기내과 15:30~15:50 -
Intracellular Ca²⁺ dysregulation links lipotoxicity to defective autophagy
오병철 가천의대 생리학교실 15:50~16:10 -
In vitro modeling of atherosclerosis using iPSC-derived blood vessel organoids
김다현 성신여대 바이오생명공학과 16:10~16:30 - Panel Discussion 16:30~17:00